Eli Lilly has axed another trial of a gene therapy acquired in its $1 billion Prevail Therapeutics buyout, further denting the drugmaker’s chances of delivering a return on its investment.
Eli Lilly has axed another trial of a gene therapy acquired in its $1 billion Prevail Therapeutics buyout, further denting the drugmaker’s chances of delivering a return on its investment.
